Renalytix expands US footprint with three new clinical partnerships

Renalytix completed clinical integrations of its FDA‑approved KidneyIntelX.dkd diagnostic into the EHRs of three US providers (Joseph P. Addabbo Family Health Center; Central Florida Kidney Specialists; The Kidney Experts PLLC) in Q4 2025, with initial patient testing underway and modest starting volumes expected to grow as practices adopt single‑click ordering. The company is working with Tempus AI (collaboration started September 2025) to drive broader uptake among diabetes and kidney‑disease populations, and management (CEO James McCullough) will give a fuller trading and progress update in February after attending the JP Morgan Healthcare Conference.

Analysis

Market structure: Renalytix (AIM:RENX / OTC:RNLXY) and Tempus (TEM) win if point-of-care kidney-risk testing becomes standard—early adopters (nephrology networks, large FQHCs) gain clinical differentiation and referral capture; legacy end-stage providers (e.g., dialysis capacity players) are neutral-to-mildly exposed only over multi-year horizons. Integrations that make ordering a one-click EHR action materially lower friction; if usage grows from low hundreds to thousands of tests per site within 6–12 months, addressable revenue could scale rapidly given per-test pricing (implied ARPU uplift of $50–$200/test). Cross-asset: small-cap diagnostics rally likely; healthcare credit spreads tightness may follow if revenue visibility improves, FX impact minimal, and options vol rises around the February update/JP Morgan commentary.

Risk assessment: Tail risks include CMS reimbursement cuts, adverse FDA/regulatory developments, major data breach at Tempus, or failed lab partnerships—each could erase >50% of market value in weeks. Immediate (days) risk centers on sentiment around JP Morgan commentary; short-term (weeks/months) hinge on February trading update and early volume trajectory; long-term (12–36 months) depends on payer coverage and demonstrated outcomes linking tests to avoided CKD progression. Hidden dependencies: success requires deep EHR+lab workflows, long sales cycles to large health systems, and Tempus’ commercial pipeline; losing one large partner could halve projected growth. Catalysts: Feb trading update, Tempus commercial rollouts in next 3–9 months, CMS coding decisions in 6–12 months.

Key Decisions for Investors

• Establish a tactical 2–3% long position in RENX/RNLXY (AIM/OTC) ahead of the February update, sized small due to OTC liquidity; set a hard stop-loss at -30% and target +40–80% upside over 3–12 months if guidance shows >25% QoQ test-volume growth.
• Buy a 3–6 month call spread on TEM (size 1–2% of portfolio) to capture revenue acceleration from Tempus integrations—use a defined-cost structure (debit spread) to cap downside; widen strike selection to keep premium <1% portfolio and target 2x+ payoff if TEM announces material new enterprise rollouts within 90 days.
• Execute a small pair trade: long RENX (1–2%) and short 1% of a large dialysis/CKD legacy operator (e.g., FMS or DVA) as a hedge against long-term clinical adoption reducing acute-care intensity; increase short if RENX demonstrates measurable reduction in downstream utilization (>=5% in a partnered population) within 12–24 months.
• Reassess and trim positions within 30–60 days if (a) February update shows <10% month-over-month test volume growth, (b) no Tempus-enabled enterprise go-lives announced in next 90 days, or (c) CMS signals adverse reimbursement trends; otherwise scale up to double initial sizes over 6–12 months.